$PIII

P3 Health Partners Inc. (PIII): Submission of Matters to a Vote of Security Holders

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. piii-20260609 0001832511 false 0001832511 2026-06-09 2026-06-09 0001832511 us-gaap:CommonClassAMember 2026-06-09 2026-06-09 0001832511 us-gaap:WarrantMember 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSU

Original reporting
Published Jun 9, 2026, 9:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$PIII
Neutral
medium confidence
Mentioned
$PIII
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PIIINeutralLow
01

Why it matters

Proposals 2–4 were approved, including Nasdaq Rule 5635(d) approval to issue up to 3,341,130 Class A shares upon exercise of outstanding warrants held by VBC Growth SPV 5, LLC.

02

Market read

The only potentially tradable item is the approved warrant-related share issuance authorization, which can influence dilution/warrant overhang expectations.

03

What to watch

Traders may focus on whether warrant holders are likely to exercise soon versus later, which is not quantified in the filing.

Relevance 6/10Novelty 4/10Timing: after-hours/filing update from June 9, 2026 annual meeting results

Background

The SEC 8-K reports matters submitted to a vote at P3 Health Partners’ 2026 annual meeting on June 9, 2026.

Company-level read

Ticker impact

$PIIINeutralMedium confidence
Context

P3 Health Partners reported 2026 annual meeting voting results, including approval to issue up to 3,341,130 shares on warrant exercise.

Expected impact

Likely limited near-term impact; any move would be driven by how traders price potential dilution from warrant exercises.

Evidence & confidence

The filing is a corporate governance/authorization update (not a new financing or deal), but it explicitly approves a defined share issuance amount tied to warrants.

Market effects

Minimal; this is company-specific governance and warrant-share issuance mechanics.

None indicated.

None indicated.

Counterpoint

Even with approval, actual warrant exercise timing/likelihood may be low, so dilution may not materialize soon.

Key entities

  • P3 Health Partners Inc.

    Company filing the 8-K; held annual meeting and reported voting outcomes.

  • VBC Growth SPV 5, LLC

    Holds outstanding Class A common stock warrants whose exercise could trigger issuance of up to 3,341,130 shares.

  • BDO USA, P.C.

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$PIIIHigh

P3 Health Partners Inc. (PIII): Results of Operations and Financial Condition

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 piii-20260810xexx991.htm EX-99.1 Document Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 H

$PIIIMedAI 8/10

Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Rises By 293.3%

P3 Health Partners (NASDAQ:PIII) reported short interest of 283,541 shares as of May 15, up 293.3% from 72,094 on April 30; about 4.8% of shares are sold short, with a days-to-cover ratio near 0.0. The stock fell 26% on Friday to $12.18. UBS and Lake Street set $14 targets; TD Cowen reiterated hold. The company reported Q1 EPS of $0.32 on revenue of $386.39M.

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

$AHRMedAI 8/10

American Healthcare REIT prices $712M stock offering

American Healthcare REIT (NYSE:AHR) priced an underwritten public offering of 13.25 million common shares via forward sale agreements, expecting about $712.2 million in gross proceeds before expenses. The deal may add 1.9875 million shares via a 30-day option. Proceeds are expected on physical settlement about 24 months later for an operating partnership acquisition and other uses.

$NVDAMedAI 8/10

Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants

Nvidia said it has signed memorandums of understanding with Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs and KKR to mobilize up to $500 billion in third-party capital for AI infrastructure financing. The plan, confirmed after an FT report that weighed on NVDA shares, aims to support data-center buildouts for Nvidia customers and could broaden Nvidia’s role beyond chips. Final terms are pending.

$INTCMedAI 8/10

Why Intel Stock Is Down Today

Intel (NASDAQ: INTC) shares fell Monday after the company announced a $15 billion stock offering. Intel said the proceeds will fund AI chip design and manufacturing, citing demand for physical AI, custom silicon, and advanced packaging. Intel also raised projected 2026 capex to over $20 billion and indicated higher capex in 2027.